The Drug Enforcement Administration (DEA) says it has no problem with reopening the record for a hearing on the Trump administration’s marijuana rescheduling proposal to include a federal watchdog report that found there are “gaps” in the government’s process for evaluating controlled substances—though it doesn’t want further briefings on the matter.
Opponents of the reform, meanwhile, are pushing to further delay a decision in the proceedings by asking the judge to order a new round of testimony and discovery.
Opponents of cannabis rescheduling had asked that the recent Government Accountability Office (GAO) report on drug scheduling be included in the record, and DEA Chief Administrative Law Judge Derek Julius last month paused the proceedings and ordered DEA to weigh in on whether the document should be made a part of the process.
DEA’s newly filed brief argues that it defers to the judge on whether the GAO report should be included in the record, but it opposes opponents’ request for additional briefings to be ordered concerning what the report’s findings mean for cannabis rescheduling.
Those opponents have “mischaracterized the GAO Report and its impact” on the marijuana rescheduling process, the agency said, adding that it “does not present any new
Read full article on Marijuana Moment
